Characteristics of patients who are initiated on long-acting buprenorphine (Buvidal®) in France: A retrospective cross-sectional study.

Fiche publication

Date publication

octobre 2024

Journal

Therapie

Auteurs

Membres identifiés du Cancéropôle Est :
Pr TROJAK Benoît

Tous les auteurs :
Deschenau A, Trojak B, Brousse G, Blecha L, Azuar J, Chappuy M, Touchon B, Kosim M, Rolland B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39455304

Résumé

The long-acting buprenorphine Buvidal® is a recent type of opioid agonist treatment (OAT) used for opioid use disorder (OUD). It was initially suggested to preferentially use Buvidal® for specific OUD populations, including people in prison, or patients in recovery and on sublingual buprenorphine. We conducted a national study to examine whether the profile of patients treated with Buvidal® in France matched these initial recommendations.